查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1766265

人类乳突病毒疫苗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Human Papillomavirus Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024年，全球人类乳突病毒疫苗市场规模达54亿美元，预计到2034年将以10.1%的复合年增长率成长，达到141亿美元。这一增长主要源自于HPV感染发生率的上升，HPV感染是全球子宫颈癌、肛门癌、口咽癌和其他肛门生殖器癌的原因。人们对HPV相关癌症的认识不断提高，以及疫苗接种计划的重要性日益凸显，进一步推动了市场成长。已开发国家和发展中国家HPV相关疾病负担的不断加重，加上公共卫生部门为推广广泛免疫接种和子宫颈癌治疗所做的努力，是推动市场成长的重要因素。

人类乳突病毒疫苗市场 - IMG1

此外，男性HPV感染率的上升以及性别中立疫苗接种策略的采用，扩大了目标族群，并刺激了HPV疫苗的需求。重组DNA技术和类病毒颗粒平台等疫苗技术的进步，正在推动下一代疫苗的开发，这些疫苗可提供更广泛的保护和更持久的免疫力。此外，新兴製造商正专注于本地生产，以提供价格合理的疫苗，满足发展中地区日益增长的需求。 HPV疫苗市场以预防HPV感染的疫苗的开发、生产和分销为中心，主要透过青少年和年轻人的免疫接种计划进行。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 54亿美元
预测值 141亿美元
复合年增长率 10.1%

市场按类型细分为二价疫苗、四价疫苗和九价疫苗。 2024年，九价疫苗占最大份额，价值39亿美元。随着人们对HPV相关癌症认识的提高，医疗保健提供者和政府优先考虑针对致癌性最强的HPV病毒株的疫苗。九价疫苗可预防九种高风险HPV类型（16、18、31、33、45、52和58型），提供更广泛的覆盖范围，满足关键的公共卫生需求。政府的免疫接种计划在九价疫苗普及率的提高中发挥了关键作用。

2024年，女性市场占据市场主导地位，预计复合年增长率将达到9.9%。由于HPV感染与子宫颈癌密切相关，疫苗接种计画主要针对女性，以降低HPV相关疾病的发生率。公共卫生政策和国际建议强调女性免疫接种，这显着刺激了需求。在公众宣传活动和非政府组织的支持下，女性健康意识和教育的增强，提高了女孩和年轻女性的疫苗接种率。父母和监护人日益增长的参与度也巩固了这个市场的主导地位。

2024年，美国人乳突病毒疫苗市场规模达22亿美元。美国HPV病例的不断增加推动了对预防性疫苗的需求。公共卫生措施、高疾病负担、强大的医疗基础设施以及政府对预防性医疗保健的投入增加是推动市场成长的关键因素。性别中立的疫苗接种政策和学校免疫计划持续推动美国国内的需求。

人类乳突病毒疫苗市场的主要参与者包括Inovio Pharmaceuticals、印度血清研究所、Recbio、葛兰素史克、默克、沃森生物、Genexine、赛诺菲巴斯德、厦门万泰和玉溪泽润生物。 HPV疫苗市场的公司专注于创新，投资开发能够提供更广泛、更持久保护的下一代疫苗。与研究机构和生物技术公司的策略合作伙伴关係能够加速产品开发和监管批准。

扩大生产能力并增强分销网络有助于满足全球日益增长的需求，尤其是在发展中地区。企业也透过与当地製造商合作来降低成本，优先考虑价格可负担性和可及性。此外，有针对性的宣传活动和倡导活动促进了疫苗的普及，支持了市场成长并增强了其全球影响力。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
    • 供应商格局
    • 每个阶段的增值
    • 影响价值链的因素
  • 产业衝击力
    • 成长动力
      • HPV相关癌症盛行率上升
      • 日益转向性别中立的疫苗接种政策
      • 不断加强的认知与教育活动
      • 疫苗研发技术进步
    • 产业陷阱与挑战
      • 先进疫苗成本高昂
      • 缺乏大规模免疫基础设施
    • 市场机会
      • 扩大发展中国家的免疫计划
      • 疫苗分发中的公私合作
  • 成长潜力分析
  • 监管格局
    • 北美洲
    • 欧洲
    • 亚太地区
  • 管道分析
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与协作
    • 新产品发布

第五章：市场估计与预测：按类型，2021 年至 2034 年

  • 主要趋势
  • 二价
  • 四价
  • 九价

第六章：市场估计与预测：按适应症，2021 年至 2034 年

  • 主要趋势
  • 子宫颈癌
  • 阴道癌及外阴癌
  • 肛门癌
  • 口咽癌
  • 其他适应症

第七章：市场估计与预测：依性别，2021 年至 2034 年

  • 主要趋势
  • 女性
  • 男性

第八章：市场估计与预测：按配销通路，2021 年至 2034 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第九章：市场估计与预测：按地区，2021 年至 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • Genexine
  • GlaxoSmithKline
  • Inovio Pharmaceuticals
  • Merck
  • Recbio
  • Sanofi Pasteur
  • Serum Institute of India
  • Walvax Biotechnology
  • Xiamen Innovax
  • Yuxi Zerun Biotech
简介目录
Product Code: 14103

The Global Human Papillomavirus Vaccines Market was valued at USD 5.4 billion in 2024 and is estimated to grow at a CAGR of 10.1% to reach USD 14.1 billion by 2034. This expansion is largely driven by the rising incidence of HPV infections, which contribute to cervical, anal, oropharyngeal, and other anogenital cancers worldwide. Increasing awareness about HPV-related cancers and the importance of vaccination programs is further propelling market growth. The rising burden of HPV-associated diseases in both developed and developing countries, coupled with public health efforts to promote widespread immunization and cervical cancer treatment, is a significant growth factor.

Human Papillomavirus Vaccines Market - IMG1

Additionally, the increasing prevalence of HPV infections in men and the adoption of gender-neutral vaccination strategies are broadening the target population and boosting demand for HPV vaccines. Advances in vaccine technology, such as recombinant DNA techniques and virus-like particle platforms, are leading to the development of next-generation vaccines that offer broader protection and longer-lasting immunity. Moreover, emerging manufacturers are focusing on local production to provide affordable vaccines and meet growing demand in developing regions. The HPV vaccines market is centered around the development, manufacture, and distribution of vaccines that prevent HPV infections, primarily delivered through immunization programs targeting adolescents and young adults.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$5.4 Billion
Forecast Value$14.1 Billion
CAGR10.1%

The market is segmented by type into bivalent, quadrivalent, and nonavalent vaccines. The nonavalent vaccine segment held the largest share in 2024, valued at USD 3.9 billion. Increased awareness of HPV-related cancers has led healthcare providers and governments to prioritize vaccines targeting the most oncogenic HPV strains. The nonavalent vaccine offers protection against nine high-risk HPV types (16, 18, 31, 33, 45, 52, and 58), providing a wider coverage that addresses critical public health needs. Government immunization initiatives have played a pivotal role in the increased adoption of nonavalent vaccines.

The female segment dominated the market in 2024 and is anticipated to grow at a CAGR of 9.9%. Since HPV infection is closely linked to cervical cancer, vaccination programs primarily target females to reduce the incidence of HPV-related diseases. Public health policies and international recommendations have emphasized female immunization, which has significantly boosted demand. Enhanced awareness and education around women's health, supported by public campaigns and NGOs, have increased vaccine uptake among girls and young women. The growing involvement of parents and caregivers has also reinforced the dominance of this segment.

U.S. Human Papillomavirus Vaccines Market was valued at USD 2.2 billion in 2024. The rising number of HPV cases in the country drives the need for preventive vaccines. Public health initiatives, a high disease burden, robust healthcare infrastructure, and increased government investments in preventive healthcare are key factors fueling market growth. Gender-neutral vaccination policies and school-based immunization programs continue to push demand within the U.S.

Key players in the Human Papillomavirus Vaccines Market include Inovio Pharmaceuticals, Serum Institute of India, Recbio, GlaxoSmithKline, Merck, Walvax Biotechnology, Genexine, Sanofi Pasteur, Xiamen Innovax, and Yuxi Zerun Biotech. Companies in the HPV vaccines market focus on innovation by investing in the development of next-generation vaccines that provide broader and longer-lasting protection. Strategic partnerships with research institutions and biotechnology firms enable accelerated product development and regulatory approvals.

Expanding manufacturing capacities and enhancing distribution networks help meet rising global demand, especially in developing regions. Firms are also prioritizing affordability and accessibility by collaborating with local manufacturers to reduce costs. Additionally, targeted awareness campaigns and advocacy efforts promote vaccine adoption, supporting market growth and strengthening their presence worldwide.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumption and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional
    • 2.2.2 Type
    • 2.2.3 Indication
    • 2.2.4 Gender
    • 2.2.5 Distribution channel
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of HPV-related cancers
      • 3.2.1.2 Increasing shift toward gender-neutral vaccination policies
      • 3.2.1.3 Growing awareness and education campaigns
      • 3.2.1.4 Technological advancements in vaccine development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced vaccines
      • 3.2.2.2 Lack of infrastructure for mass immunization
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expanding immunization programs in developing countries
      • 3.2.3.2 Public-private partnerships in vaccine distribution
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Pipeline analysis
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Bivalent
  • 5.3 Quadrivalent
  • 5.4 Nonavalent

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Cervical cancer
  • 6.3 Vaginal and vulvar cancer
  • 6.4 Anal cancer
  • 6.5 Oropharyngeal cancer
  • 6.6 Other indications

Chapter 7 Market Estimates and Forecast, By Gender, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Female
  • 7.3 Male

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Genexine
  • 10.2 GlaxoSmithKline
  • 10.3 Inovio Pharmaceuticals
  • 10.4 Merck
  • 10.5 Recbio
  • 10.6 Sanofi Pasteur
  • 10.7 Serum Institute of India
  • 10.8 Walvax Biotechnology
  • 10.9 Xiamen Innovax
  • 10.10 Yuxi Zerun Biotech